# Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
Canonical URL: https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026
Ticker: LYEL
Company: Lyell Immunopharma
Source: Lyell Immunopharma
Published: 2026-05-06 20:05 EST
Original Source URL: https://ir.lyell.com
## Summary

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027 PiNACLE-H2H, a first of its kind Phase 3 clinical

## Article Body
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027 PiNACLE-H2H, a first of its kind Phase 3 clinical
## Recent Company News
- 2026-06-01 12:00 EST — [Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Lyell Immunopharma
- 2026-05-12 12:00 EST — [Lyell Immunopharma Announces Participation in May Investor Conferences](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-may-investor-conferences) — Source: Lyell Immunopharma
- 2026-05-06 20:05 EST — [Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-first-quarter-2026) — Source: Lyell Immunopharma
- 2026-04-07 12:00 EST — [Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference) — Source: Lyell Immunopharma
- 2026-03-12 20:05 EST — [Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-q4-and-full-year-2025-business-and-financial-results) — Source: Lyell Immunopharma
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)